Short-Acting Insulin Market Revenues to Reach USD 8.29 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 18, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, Aug. 18, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Short-Acting Insulin Market Report (2023-2028)," the market is estimated at USD 6.99 billion in 2023....
Mexico Insulin Drugs and Delivery Devices Market Revenues to Reach USD 566.91 million by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 09, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, Aug. 09, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Mexico Insulin Drugs and Delivery Devices Market Report (2023-2028)," the market is estimated at USD...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
July 11, 2023 09:58 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Middle East and Africa Human Insulin Market is anticipated to register a CAGR of greater than 4% during 2023 – 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
April 05, 2023 09:00 ET
|
Mordor Intelligence
Hyderabad, April 05, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Middle East and Africa Human Insulin Market - (2023 – 2028),” the market is expected to register a...
IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies
October 05, 2021 07:00 ET
|
IpiNovyx
Participating Investors include Viva BioInnovator, Eli Lilly and Company, Opaleye Management, Orange Grove Bio and Alexandria Venture Investments Foundational Science Stems From Landmark Research at...
Global Schizophrenia Drug Market is estimated to be US$ 9.8 Bn by 2030 with a CAGR of 2.7% during the forecast period - by PMI
February 24, 2021 10:05 ET
|
PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The global schizophrenia drug market accounted for US$ 7.5 Bn in 2020 and is estimated to be US$ 9.8 Bn by 2030 and is anticipated to register a CAGR of...
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 12, 2021 10:05 ET
|
PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
December 16, 2020 14:56 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches...
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
December 16, 2020 12:37 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
October 20, 2020 19:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...